Nexgel (NXGL) Cash from Financing Activities (2018 - 2025)
Nexgel (NXGL) reported Cash from Financing Activities of -$1.0 million for Q4 2025, down 162.34% on a YoY basis from $1.7 million in Q4 2024, and down 154.05% quarter-over-quarter from $1.9 million in Q3 2025.
Nexgel (NXGL) Cash from Financing Activities (2018 - 2025) Analysis & Trends
Nexgel has reported Cash from Financing Activities for 8 years, with the latest figure at -$1.0 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 162.34% year-over-year to -$1.0 million; the trailing twelve-month figure through Dec 2025 stood at $630000.0 (down 83.2% YoY), and the FY2025 full-year result was $630000.0, down 83.2% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at -$1.0 million, down from $1.9 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $13.2 million in Q4 2021, with the low at -$2.0 million in Q1 2022.
- Historically, Cash from Financing Activities has averaged $968666.7 across 5 years, with a median of $43500.0 in 2023.
- The largest YoY upside for Cash from Financing Activities was 46550.0% in 2024 against a maximum downside of 6300.0% in 2024.
- Nexgel's Cash from Financing Activities stood at $13.2 million in 2021, then tumbled by 101.14% to -$150000.0 in 2022, then jumped by 296.0% to $294000.0 in 2023, then soared by 468.03% to $1.7 million in 2024, then tumbled by 162.34% to -$1.0 million in 2025.
- The last three Cash from Financing Activities figures came in at -$1.0 million (Q4 2025), $1.9 million (Q3 2025), and -$40000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Nexgel | 4.18 Mn | 2.81 Mn | 819,000.00 | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.04 Mn |
| Dec 31, 2025 | -1.04 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | -40,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | 1.67 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -64,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Dec 31, 2023 | 294,000.00 |
| Dec 31, 2023 | 294,000.00 |
| Sep 30, 2023 | 88,000.00 |
| Sep 30, 2023 | 88,000.00 |